1.Study of chemical-physical properties and of the physiopathological role of proteins and other macromolecules.

2. Molecular basis of Sorcin activity: calcium-dependent signal transduction, Multidrug resistance, cancer, neurodegenerative diseases.

3. Structural and functional studies on the enzymes of the unique thiol-based redox metabolism of Leishmania, common to all parasites of the Trypanosomatidae family but absent in man.  Development of new therapeutic strategies against leishmaniasis.

4. Drug delivery and novel therapeutic strategies against cancer and neurodegenerative diseases

SELECTED RECENT PUBLICATIONS (last 12 years)

1.. Colotti G.*, Ilari A, Boffi A, Morea V. 

“Metals and Metal derivatives in Medicine.” 

Mini Rev Med Chem. Vol. 13, 2, 211-221, 2013.

2. Trnkova L.; Ricci D.; Grillo C.; Colotti, G.; Altieri F.

“Green tea catechins can bind and modify ERp57/PDIA3 activity.”

Biochimica et Biophysica Acta. Vol. 1830, 3, 2671-2682, 2013.

3. Baiocco P.; Poce G.; Alfonso S.; Cocozza M.; Porretta GC.; Colotti G.*; Biava M.; Moraca F.; Botta M.; Yardley V.; Fiorillo A.; Lantella A.; Malatesta F.; Ilari A.

“Inhibition of Leishmania infantum Trypanothione Reductase by Azole-Based Compounds: a Comparative Analysis with Its Physiological Substrate by X-ray Crystallography.”

ChemMedChem. Vol. 8, 7, 1175-1183, 2013.

4. Colotti G.*, Ilari A., Fiorillo A., Baiocco P., Cinellu MA, Maiore L., Scaletti F, Gabbiani C, Messori L.

“Metal‐Based Compounds as Prospective Antileishmanial Agents: Inhibition of Trypanothione Reductase by Selected Gold Complexes.”

ChemMedChem. Vol. 8, 10, 1634-1637, 2013.

5. Colotti G.*; Baiocco P.; Fiorillo A.; Boffi A.; Poser E.; Di Chiaro F.; Ilari A.

“Structural insights into the enzymes of the trypanothione pathway: targets for antileishmaniasis drugs.”

Future Medicinal Chemistry. Vol. 5, 15, 1861-1875, 2013.

6. Lalioti VS.; Ilari A; O’Connell DJ.; Poser E.; Sandoval IV.; Colotti G.* 

"Sorcin Links Calcium Signaling to Vesicle Trafficking, Regulates Polo-like Kinase 1 and is Necessary for Mitosis."

PLoS One. 2014, Jan 10; 9(1), PONE-D-13-29980R1 10.1371/journal.pone.0085438, 2014.

7. Perli E., Giordano C., Pisano A, Montanari A., Campese AF, Reyes A, Ghezzi D, Nasca A, Tuppen HA, Orlandi M, Di Micco P, Poser E, Taylor RW, Colotti G., Francisci S, Morea V, Frontali L, Zeviani M, d’Amati G.

“The isolated carboxy-terminal domain of human mitochondrial leucyl-tRNA synthetase rescues the pathological phenotype of mitochondrial tRNA mutations in human cells.”

EMBO Mol. Med. 2014 Feb 1; 6 (2):169-82. doi: 10.1002/emmm.201303198. 

8. Sechi S., Colotti G., Belloni G., Mattei V., Frappaolo A., Raffa G.D., Fuller M.T., Giansanti M.G. 

 “GOLPH3 Is Essential for Contractile Ring Formation and Rab11 Localization to the Cleavage Site during Cytokinesis in Drosophila melanogaster. “

PLoS Genet. 2014 May 1;10(5):e1004305. doi: 10.1371/journal.pgen.1004305.

9. Masciarelli S, Quaranta R, Iosue I, Colotti G, Padula F, Varchi G, Fazi F, Del Rio A. 

“A small-molecule targeting the microRNA binding domain of argonaute 2 improves the retinoic acid differentiation response of the acute promyelocytic leukemia cell line NB4.”

ACS Chem Biol. 2014 Aug 15;9(8):1674-9. doi: 10.1021/cb500286b. Epub 2014 Jun 11. PubMed PMID: 24914804.

10. Colotti G*, Poser E, Fiorillo A, Genovese I, Chiarini V, Ilari A. 

“Sorcin, a calcium binding protein involved in the multidrug resistance mechanisms in cancer cells.” 

Molecules. 2014 Sep 5;19(9):13976-89. doi: 10.3390/molecules190913976. PubMed PMID: 25197934.

11. Sechi S., Frappaolo A., Belloni G., Colotti G., Giansanti MG.

 “The multiple cellular functions of the oncoprotein Golgi phosphoprotein 3” 

Oncotarget 2015, 6 (6), 3493.

12. Ilari A., Fiorillo A., Baiocco P., Poser E., Angiulli G., Colotti G.*
“Targeting Polyamine Metabolism for Finding New Drugs Against Leishmaniasis: A Review”
Mini reviews in medicinal chemistry 2015, 15 (3), 243-252.

13. Angiulli G, Lantella A, Forte E, Angelucci F, Colotti G, Ilari A, Malatesta F.

“Leishmania infantum trypanothione reductase is a promiscuous enzyme carrying an

NADPH:O(2) oxidoreductase activity shared by glutathione reductase”. 

Biochim Biophys Acta. 2015 Sep;1850(9):1891-7. doi:10.1016/j.bbagen.2015.05.022. 

14. Brindisi M, Brogi S, Relitti N, Vallone A, Butini S, Gemma S, Novellino E, Colotti G, Angiulli G, Di Chiaro F, Fiorillo A, Ilari A, Campiani G.

“Structure-based discovery of the first non-covalent inhibitors of Leishmania

major tryparedoxin peroxidase by high throughput docking”. 

Sci Rep. 2015 May 7;5:9705. doi: 10.1038/srep09705. 

15. Ilari A, Fiorillo A, Poser E, Lalioti VS, Sundell GN, Ivarsson Y, Genovese I, Colotti G*.

“Structural basis of Sorcin-mediated calcium-dependent signal transduction”. 

Sci Rep. 2015 Nov 18;5:16828. doi: 10.1038/srep16828.  

16. Perli E, Fiorillo A, Giordano C, Pisano A, Montanari A, Grazioli P, Campese AF, Di Micco P, Tuppen HA, Genovese I, Poser E, Preziuso C, Taylor RW, Morea V, Colotti G*, d'Amati G.

“Short peptides from leucyl-tRNA synthetase rescue disease-causing mitochondrial tRNA point mutations”.

Hum Mol Genet. 2016 Mar 1;25(5):903-15. doi: 10.1093/hmg/ddv619. 

17. Digilio, F.A., Lanati, A., Bongiovanni, A., Colotti G., Lacerra, G., Liguori, G.L. 

“Quality-based model for Life Sciences research guidelines”. 

Accreditation and Quality Assurance 2016; 21(3): 221-230.

18. Fracasso, G., Falvo, E., Colotti, G., (...), Arcovito, A., Ceci, P. 

“Selective delivery of doxorubicin by novel stimuli-sensitive nano-ferritins overcomes tumor refractoriness”.

Journal of Controlled Release 2016; 239: 10-18.

19. Saccoliti F, Angiulli G, Pupo G, Pescatori L, Madia VN, Messore A, Colotti G, Fiorillo A, Scipione L, Gramiccia M, Di Muccio T, Di Santo R, Costi R, Ilari A.

“Inhibition of Leishmania infantum trypanothione reductase by diaryl sulfide

derivatives”. 

J Enzyme Inhib Med Chem. 2017;32(1):304-310. 

20. Ilari A, Fiorillo A, Genovese I, Colotti G*. 

Polyamine-trypanothione pathway: an update. 

Future Med Chem. 2017 Jan;9(1):61-77. 

21. Poser E, Genovese I, Masciarelli S, Bellissimo T, Fazi F, Colotti G*. 

Surface Plasmon Resonance: A Useful Strategy for the Identification of Small Molecule

Argonaute 2 Protein Binders. Methods Mol Biol. 2017;1517:223-237. 

22. Bellissimo T, Masciarelli S, Poser E, Genovese I, Del Rio A, Colotti G, Fazi F. 

“Small Molecules Targeting the miRNA-Binding Domain of Argonaute 2: From

Computer-Aided Molecular Design to RNA Immunoprecipitation”. 

Methods Mol Biol. 2017;1517:211-221. 

23. Mosca L, Falvo E, Ceci P, Poser E, Genovese I, Guarguaglini G, Colotti G*

“Use of Ferritin-Based Metal-Encapsulated Nanocarriers as Anticancer Agents”

Applied Sciences 2017, 7, 101.

24. Asteriti IA, Daidone F, Colotti G, Rinaldo S, Lavia P, Guarguaglini G, Paiardini A.
“Identification of small molecule inhibitors of the Aurora-A/TPX2 complex.”
Oncotarget. 2017 Mar 31. 

Amino Acids. 2017. doi: 10.1007/s00726-017-2417-2.  

27: Ferrara M, Sessa G, Fiore M, Bernard F, Asteriti IA, Cundari E, Colotti G, Ferla S, Desideri M, Buglioni S, Trisciuoglio D, Del Bufalo D, Brancale A, Degrassi F.
“Small molecules targeted to the microtubule-Hec1 interaction inhibit cancer cell growth through microtubule stabilization”. 

Oncogene. 2017 Sep 18. doi:10.1038/onc.2017.320. 

28: Colotti G*, Fiorillo A, Ilari A.

“Metal-and metalloid-containing drugs for the treatment of trypanosomatid diseases.”

Frontiers in biosciences. 2018. 23, 954-966. doi: 10.2741/4628.

29: De Cola A, Franceschini M, Di Matteo A, Colotti G, Celani R, Clemente E, Ippoliti R, Cimini AM, Dhez AC, Vallée B, Raineri F, Cascone I, Destouches D, De Laurenzi V, Courty J, Federici L.

“N6L pseudopeptide interferes with nucleophosmin protein-protein interactions and sensitizes leukemic cells to chemotherapy.”

Cancer Letters. 2018, 412, 272-282. doi: 10.1016/j.canlet.2017.10.038

30: Falvo E, Malagrinò F, Arcovito A, Fazi F, Colotti G, Tremante E, Di Micco P, Braca A, 

Opri R, Giuffrè A, Fracasso G, Ceci P. 

“The presence of glutamate residues on the PAS sequence of the stimuli-sensitive nano-ferritin improves in vivo biodistribution and mitoxantrone encapsulation homogeneity.” 

J Control Release. 2018 Feb 20;275:177-185. doi: 10.1016/j.jconrel.2018.02.025. 

31: Ortalli M, Ilari A, Colotti G, De Ionna I, Battista T, Bisi A, Gobbi S, Rampa A, Di  

Martino RMC, Gentilomi GA, Varani S, Belluti F

“Identification of chalcone-based antileishmanial agents targeting trypanothione reductase”

European journal of medicinal chemistry 152, 527-541. doi: 10.1016/j.ejmech.2018.04.057.

32. Ilari A, Genovese I, Fiorillo F, Battista T, De Ionna I, Fiorillo A, Colotti G*. 

“Toward a Drug Against All Kinetoplastids: From LeishBox to Specific and Potent

Trypanothione Reductase Inhibitors.” 

Mol Pharm. 2018 Jun 27. doi: 10.1021/acs.molpharmaceut.8b00185.

33. Genovese I, Ilari A, Battista T, Chiarini V, Fazi F, Fiorillo A, Colotti G.*

 “Molecular bases of Sorcin-dependent resistance to chemotherapeutic agents”

 Cancer Drug Resist. 2018; 1:164-180. doi:10.20517/cdr.2018.10.

34. Kahremany S, Zhenin M, Shenberger Y, Maimoun D, Colotti G, Arad M, Shainberg

 A, Senderowitz H, Ruthstein S, Gruzman A.

 “Peptide-based development of PKA inhibitors”

 New Journal of Chemistry 2018, 42, 23:18585-18597. doi: 10.1039/C8NJ01732H.

35. Turcano L, Torrente E, Missineo A, Andreini M, Gramiccia M, Di Muccio T, Genovese

    I, Fiorillo A, Harper S, Bresciani A, Colotti G*, Ilari A.

“Identification and binding mode of a novel Leishmania Trypanothione reductase

inhibitor from high throughput screening”

PLOS Neglected Tropical Diseases 2018, 12,11:e0006969.

doi:10.1371/journal.pntd.0006969

36. Pippa S, Mannironi C, Licursi V, Bombardi L, Colotti G, Cundari E, Mollica A,  

Coluccia A, Naccarato V, La Regina G, Silvestri R, Negri R.

 “Small Molecule Inhibitors of KDM5 Histone Demethylases Increase the 

Radiosensitivity of Breast Cancer Cells Overexpressing JARID1B”

 Molecules 2019, 1, 9:1739. doi:10.3390/molecules24091739.

37. Chiarini V, Tossavainen H, Sharma V, Colotti G*.

 “NMR structure of a non-conjugatable, ADP-ribosylation associated, ubiquitin-like 

domain from Tetrahymena thermophila polyubiquitin locus”

 Biochimica et Biophysica Acta (BBA)-General Subjects 2019, 1863, 4:749. doi: 

10.1016/j.bbagen.2019.01.014.

38. Colotti G*, Saccoliti F, Gramiccia M, Di Muccio T, Prakash J, Yadav S, Kumar Dubey

V, Vistoli G, Battista T, Mocci S, Fiorillo A, Bibi A, Madia VN, Messore A, Costi R, Di Santo R, Ilari A.

“Structure-guided approach to identify a novel class of anti-leishmaniasis diaryl sulfide compounds targeting the trypanothione metabolism”

 Amino Acids 2019, 1-13. doi: 10.1007/s00726-019-02731-4.

39. Rinaldi T, Colotti G*.

 “Use of organoids in medicinal chemistry: challenges on ethics and biosecurity”

 Future Medicinal Chemistry 2019, 11 (10), 1087-1090. doi: 10.4155/fmc-2018-0341.

40. Carbo M, Brandi V, Pascarella G, Staid DS, Colotti G, Polticelli F, Ilari A, Morea V.

 “Bioinformatics analysis of Ras homologue enriched in the striatum, a potential target for Huntington's disease therapy”

 International journal of molecular medicine 2019, 4373. doi: 10.3892/ijmm.2019.4373.

41. Battista T, Fiorillo A, Chiarini V, Genovese I, Ilari A, Colotti G*.
“Roles of Sorcin in Drug Resistance in Cancer: One Protein, Many Mechanisms, for a Novel Potential Anticancer Drug Target" 
Cancers (Basel). 2020 Apr 6;12(4):887. doi: 10.3390/cancers12040887

42. Caroselli S, Zwergel C, Pirolli A, Sabatino M, Xu Z, Kirsch G, Mai A, Colotti G, Altieri F, Canipari R, Valente S, Ragno R.
“Discovery of the First Human Arylsulfatase A Reversible Inhibitor Impairing Mouse Oocyte Fertilization”.
ACS Chem Biol. 2020 Jun 19;15(6):1349-1357. doi: 10.1021/acschembio.9b0099.

43. Genovese I, Carotti A, Ilari A, Fiorillo A, Battista T, Colotti G, Ivarsson Y.
“Profiling calcium-dependent interactions between Sorcin and intrinsically disordered regions of human proteome".
Biochim Biophys Acta Gen Subj. 2020 Aug;1864(8):129618. doi:10.1016/j.bbagen.2020.129618.

44. Perli E, Pisano A, Pignataro MG, Campese AF, Pelullo M, Genovese I, de Turris V, Ghelli AM, Cerbelli B, Giordano C, Colotti G, Morea V, d'Amati G. 
“Exogenous peptides are able to penetrate human cell and mitochondrial membranes, stabilize mitochondrial tRNA structures, and rescue severe mitochondrial defects".
FASEB J. 2020 Jun;34(6):7675-7686. doi: 10.1096/fj.201903270R.

45. Battista T, Colotti G, Ilari A, Fiorillo A.
“Targeting Trypanothione Reductase, a Key Enzyme in the Redox Trypanosomatid Metabolism, to Develop New Drugs against Leishmaniasis and Trypanosomiases”.
Molecules. 2020 Apr 21;25(8):1924. doi: 10.3390/molecules25081924.

46. Colotti G*, Rinaldi T.
“The central role of gut microbiota in drug metabolism and personalized medicine”.
Future Med Chem. 2020 May 29. doi: 10.4155/fmc-2020-0023.

47. Turcano L, Battista T, De Haro ET, Missineo A, Alli C, Paonessa G, Colotti G, Harper S, Fiorillo A, Ilari A, Bresciani A.
“Spiro-containing derivatives show antiparasitic activity against Trypanosoma brucei through inhibition of the trypanothione reductase enzyme”.
PLoS Negl Trop Dis. 2020 May 21;14(5):e0008339. doi: 10.1371/journal.pntd.0008339.

48. Mascia A, Cirafici AM, Bongiovanni A, Colotti G, Lacerra G, Di Carlo M, Digilio FA, Liguori GL, Lanati A, Kisslinger A.
“A failure mode and effect analysis (FMEA)-based approach for risk assessment of scientific processes in non-regulated research laboratories.
Accreditation And Quality Assurance. 2020. doi: 10.1007/s00769-020-01441-9. 

49. Genovese I, Giamogante F, Barazzuol L, Battista T, Fiorillo A, Vicario M, D'Alessandro G, Cipriani R, Limatola C, Rossi D, Sorrentino V, Poser E, Mosca L, Squitieri F, Perluigi M, Arena A, van Petegem F, Tito C, Fazi F, Giorgi C, Calì T, Ilari A, Colotti G*. 
“Sorcin is an early marker of neurodegeneration, Ca2+ dysregulation and endoplasmic reticulum stress associated to neurodegenerative diseases.”
Cell Death Dis. 2020 Oct 15;11(10):861. doi: 10.1038/s41419-020-03063-y.

50. Flego M, Colotti G, Ascione A, Dupuis ML, Petrucci E, Riccioni R, Andreotti M, Raggi C, Boe A, Barca S, Gellini M, Vella S, Mallano A. 
“Isolation and preliminary characterization of a human 'phage display'-derived antibody against neural adhesion molecule-1 antigen interfering with fibroblast growth factor receptor-1 binding.” 
Hum Antibodies. 2020 Oct 23. doi: 10.3233/HAB-200431.

51. Mosca L, Ilari A, Fazi F, Assaraf YG, Colotti G*.
“Taxanes in cancer treatment: Activity, chemoresistance and its overcoming.”
Drug Resist Updat. 2021 Jan;54:100742. doi: 10.1016/j.drup.2020.100742.

52. Chiarini V, Fiorillo A, Camerini S, Crescenzi M, Nakamura S, Battista T, Guidoni L, Colotti G*, Ilari A.
“Structural basis of ubiquitination mediated by protein splicing in early Eukarya.”
Biochim Biophys Acta Gen Subj. 2021 May;1865(5):129844. doi: 10.1016/j.bbagen.2021.129844.

53. Battista T, Pascarella G, Staid DS, Colotti G, Rosati J, Fiorillo A, Casamassa A, Vescovi AL, Giabbai B, Semrau MS, Fanelli S, Storici P, Squitieri F, Morea V, Ilari A. 
“Known Drugs Identified by Structure-Based Virtual Screening Are Able to Bind Sigma-1 Receptor and Increase Growth of Huntington Disease Patient-Derived Cells.”
Int J Mol Sci. 2021 Jan 28;22(3):1293. doi: 10.3390/ijms22031293.

54. Colotti G, Failla CM, Lacal PM, Ungarelli M, Ruffini F, Di Micco P, Orecchia A, Morea V. 
"Neuropilin-1 is required for endothelial cell adhesion to soluble vascular endothelial growth factor receptor 1".
FEBS Journal 2021, 10.1111. https://doi.org/10.1111/febs.16119

55. Valentini E, D'Aguanno S, Di Martile M, Montesano C, Ferraresi V, Patsilinakos A, Sabatino M, Antonini L, Valente S, Mai A, Colotti G, Ragno R, Trisciuoglio D, Del Bufalo D.
"Targeting the anti-apoptotic Bcl-2 family proteins: machine learning virtual screening and biological evaluation of new small molecules".
Theranostics 2021; 12(5):2427-2444. doi:10.7150/thno.64233.

56. Fiorillo A, Morea V., Colotti G., Ilari A. 
"Huntingtin ubiquitination mechanisms and novel possible therapies to decrease the toxic effects of mutated Huntingtin".
Journal of Personalized Medicine, 2021, 11, 1309. doi: 10.3390/jpm11121309.

57: Di Risola D, Ricci D, Marrocco I, Giamogante F, Grieco M, Francioso A, Vasco-Vidal A, Mancini P, Colotti G*, Mosca L, Altieri F.
ERp57 chaperon protein protects neuronal cells from Aβ-induced toxicity.
J Neurochem. 2022; 162(4):322-336. doi: 10.1111/jnc.15655. 

58: Fiorillo A, Colotti G, Exertier C, Liuzzi A, Seghetti F, Salerno A, Caciolla J, Ilari A.
Innovative Approach for a Classic Target: Fragment Screening on Trypanothione Reductase Reveals New Opportunities for Drug Design.
Front Mol Biosci. 2022; 9:900882. doi: 10.3389/fmolb.2022.900882. 

59: Battista T, Federico S, Brogi S, Pozzetti L, Khan T, Butini S, Ramunno A, Fiorentino E, Orsini S, Di Muccio T, Fiorillo A, Exertier C, Di Risola D, Colotti G*, Gemma S, Ilari A, Campiani G.
Optimization of Potent and Specific Trypanothione Reductase Inhibitors: A Structure-Based Drug Discovery Approach.
ACS Infect Dis. 2022; 8(8):1687-1699. doi: 10.1021/acsinfecdis.2c00325.

60: Tramonti A, Ghatge MS, Babor JT, Musayev FN, di Salvo ML, Barile A, Colotti G, Giorgi A, Paredes SD, Donkor AK, Al Mughram MH, de Crécy-Lagard V, Safo MK, Contestabile R.
Characterization of the Escherichia coli pyridoxal 5'-phosphate homeostasis protein (YggS): Role of lysine residues in PLP binding and protein stability.
Protein Sci. 2022; 31(11):e4471. doi: 10.1002/pro.4471. 

61: Madia VN, Ialongo D, Patacchini E, Exertier C, Antonelli L, Colotti G, Messore A, Tudino V, Saccoliti F, Scipione L, Ilari A, Costi R, Di Santo R.
Inhibition of Leishmania infantum Trypanothione Reductase by New Aminopropanone Derivatives Interacting with the NADPH Binding Site.
Molecules. 2023; 28(1):338. doi: 10.3390/molecules28010338.

62: Pascarella G, Antonelli L, Narzi D, Battista T, Fiorillo A, Colotti G, Guidoni L, Morea V, Ilari A. Investigation of the Entry Pathway and Molecular Nature of σ1 Receptor Ligands.
Int J Mol Sci. 2023; 24(7):6367. doi: 10.3390/ijms24076367. 

63: Zwergel C, Aventaggiato M, Garbo S, Di Bello E, Fassari B, Noce B, Castiello C, Lambona C, Barreca F, Rotili D, Fioravanti R, Schmalz T, Weyand M, Niedermeier A, Tripodi M, Colotti G, Steegborn C, Battistelli C, Tafani M, Valente S, Mai A.
Novel 1,4-Dihydropyridines as Specific Binders and Activators of SIRT3 Impair Cell Viability and Clonogenicity and Downregulate Hypoxia-Induced Targets in Cancer Cells.
J Med Chem. 2023; 66(14):9622-9641. doi: 10.1021/acs.jmedchem.3c00337. 

64: Tito C, Genovese I, Giamogante F, Benedetti A, Miglietta S, Barazzuol L, Cristiano L, Iaiza A, Carolini S, De Angelis L, Masciarelli S, Nottola SA, Familiari G, Petrozza V, Lauriola M, Tamagnone L, Ilari A, Calì T, Valdivia HH, Valdivia CR, Colotti G*, Fazi F.
Sorcin promotes migration in cancer and regulates the EGF-dependent EGFR signaling pathways.
Cell Mol Life Sci. 2023; 80(8):202. doi: 10.1007/s00018-023-04850-4.

65: Valentini E, Di Martile M, Brignone M, Di Caprio M, Manni I, Chiappa M, Sergio I, Chiacchiarini M, Bazzichetto C, Conciatori F, D'Aguanno S, D'Angelo C, Ragno R, Russillo M, Colotti G, Marchesi F, Bellone ML, Dal Piaz F, Felli MP, Damia G, Del Bufalo D.
Bcl-2 family inhibitors sensitize human cancer models to therapy.
Cell Death Dis. 2023; 14(7):441. doi: 10.1038/s41419-023-05963-1.

66: Mattioli R, Ilari A, Colotti B, Mosca L, Fazi F, Colotti G*.
Doxorubicin and other anthracyclines in cancers: Activity, chemoresistance and its overcoming.
Mol Aspects Med. 2023; 93:101205. doi: 10.1016/j.mam.2023.101205.

67: Fracasso G, Falvo E, Tisci G, Sala G, Colotti G, Cingarlini S, Tito C, Bibbo S, Frusteri C, Tremante E, Giordani E, Giacomini P, Ceci P.
Widespread in vivo efficacy of The-0504: A conditionally-activatable nanoferritin for tumor-agnostic targeting of CD71-expressing cancers.
Heliyon. 2023; 9(10):e20770. doi: 10.1016/j.heliyon.2023.e20770.

68: Atomwise AIMS Program.
“AI is a viable alternative to high throughput screening: a 318-target study”.
Scientific Reports 2024;14(1):7526. doi: 10.1038/s41598-024-54655-z.

69: Marrocco F, Falvo E, Mosca L, Tisci G, Arcovito A, Reccagni A, Limatola C, Bernardini R, Ceci P, D'Alessandro G, Colotti G*.
“Nose-to-brain selective drug delivery to glioma via ferritin-based nanovectors reduces tumor growth and improves survival rate”.
Cell Death Dis. 2024;15(4):262. doi: 10.1038/s41419-024-06653-2.

70: Exertier C, Antonelli L, Fiorillo A, Bernardini R, Colotti B, Ilari A, Colotti G*.
“Sorcin in Cancer Development and Chemotherapeutic Drug Resistance”.
Cancers (Basel). 2024 Aug 9;16(16):2810. doi: 10.3390/cancers16162810.

71: Zineddu S, Geri A, Ilari A, Colotti G, Exertier C, Fiorillo A, Antonelli L, Messori L.
“ESI MS Studies Of T. brucei Trypanothione Reductase And Its Reactions With Selected Metal Compounds”.
Eur. J. Inorg. Chem. 2024 Oct 14; doi: 10.1002/ejic.202400499.

72: Tito C, Masciarelli S, Colotti G*, Fazi F.
“EGF Receptor in organ development, tissue homeostasis and regeneration”.
J Biomed Sci. 2025 Feb 19;32(1):24. doi: 10.1186/s12929-025-01119-9.

73: Frappaolo A, Zaccagnini G, Riparbelli MG, Colotti G, Callaini G, Giansanti MG.
“PACS deficiency disrupts Golgi architecture and causes cytokinesis failures and seizure-like phenotype in Drosophila melanogaster”.
Open Biol. 2025 Feb;15(2):240267. doi: 10.1098/rsob.240267.

74: Tisci G, Rajsiglova L, Bibbo S, Ziccheddu G, Ricciardi E, Falvo E, De Laurenzi V, Sala G, Capone E, Colotti G, Arcovito A, Giacon N, Makovický P, Sushytskyi L, Lukac P, Vannucci L, Giacomini P, Ceci P.      “A first-in-class non-cytotoxic nanocarrier based on a recombinant human ferritin boosts targeted therapy, chemotherapy and immunotherapy".
Int J Biol Macromol. 2025 Apr 3;309(Pt 1):142843. doi: 10.1016/j.ijbiomac.2025.142843.

75: Exertier C, Antonelli L, Brufani V, Colotti G, Ilari A, Fiorillo A.
“Expanding the molecular landscape of fragments binding to trypanothione reductase, a legitimate target for drug design against human African trypanosomiasis". 
Frontiers in Chemical Biology. 2025, Volume 4: 1605579. doi: 10.3389/fchbi.2025.1605579

*: corresponding author

Dr. Andrea Ilari
Dr. Pierpaolo Ceci
Dr. Elisabetta Falvo
Dr. Veronica Morea
Dr. Carmelinda Savino
Dr. Annarita Fiorillo
Dr. Ilaria Genovese
Dr. Cecile Exertier
Dr. Lorenzo Antonelli
Dr. Vittorio Brufani

Prof. Francesco Fazi, Sapienza University, Rome (Italy)
Prof. Tito Calì, Università di Padova (Italy)
Prof. Luciana Mosca, Sapienza University, Rome (Italy)
Prof. Sandra Gemma, Università di Siena, Siena (Italy)

DEGREES: 

1989: degree in Biological Sciences (with honors), University of Rome "La Sapienza", Italy.
1993: Ph.D. in Biochemistry

PROFESSIONAL EXPERIENCE:

1990-1993: Ph. D. Dept. Biochemical Sciences, University Sapienza, Rome, Italy
1991-1993:  Program in Molecular Medicine and Department of Biochemistry and Molecular Biology, University of Massachusetts Medical Center, Worcester, Massachusetts.
1993-1994: CNR fellowship in Molecular Biology and Biotechnology
1994-1995: Post-doc fellowship in Medical Sciences, Faculty of Medicine, University of Rome "La Sapienza".
1996-present: Research Scientist at the Institute of Molecular Biology and Pathology, CNR (National Research Council).
2009: idoneity First Research Scientist, Physical Sciences, CNR.
2010: idoneity First Research Scientist, Life Sciences, CNR.
2014: idoneity Associate Professor (National Scientific Abilitation, 05-E2 Molecular Biology)
2017: idoneity Associate Professor (National Scientific Abilitation, 05-E1 Biochemistry)
2017: idoneity Full Professor (National Scientific Abilitation, 05-E1 Biochemistry)
2020: First Researcher, IBPM CNR
2021: idoneity Full Professor (National Scientific Abilitation, 05-E2 Molecular Biology)
2023: Research Director, IBPM CNR

TEACHING

1997-2010: Course of Molecular Biology, School of Specialization in Pathological Anatomy, Faculty of Medicine, University "Sapienza", Rome, Italy.
1997-2010: lecturer of Molecular Biology, First School of Specialization in Oncology, Faculty of Medicine, University "Sapienza", Rome, Italy.
2005: Course "Applications of Bioinformatics in Molecular and Structural Biology" Institute of Molecular Biology and Pathology, CNR.
2005: Course "Bioinformatics for Molecular and Cellular Biologists", Ph.D. in Cellular Biology, University "Sapienza", Rome, Italy.
2007: Course "Bioinformatics for Biologists", CNR.
2010: Course "Bioinformatics for Molecular Biologists", CNR. 
2011: Lecturer of the Course "Bioinformatics for biology", University L'Aquila, Italy
Since 2017: member of the Teaching Board, Ph.D. School of Biochemistry, Sapienza University, Rome
2025: Course "macromolecular Interactions", Ph.D. Schools of Biochemistry and of Life Science

RECENT RESEARCH PROJECTS:

Operative Unit Coordinator, PRIN 2022 Tryp4Leish: a One Health approach for the structure-based discovery of anti-leishmania agentsinterfering with the trypanothione-based defense system in trypanosomatids, 2022HYF8KS.
Italian Substitute, COST (European Cooperation in Science and Technology) Harmonizing standardisation strategies to increase efficiency and competitiveness of European life-science research (CHARME).
Coordinator of Work Package (WP2): Flagship Project Nanomax: “Nanotechnology-based Diagnostics In Neurological diseases and Experimental oncology” Acronym: “NADINE” Scientific Coordinator Prof. A. Boffi.
Coordinator of the project: “Molecular complexes of sorcin and E-Syt1 in the generation and regulation of calcium-dependent cellular functions”, CNR-CSIC 2010-2012.
Coordinator of Operative Unit, Project "Pemphigus vulgaris as a paradigm of autoantibody-mediated organ-specific autoimmune disorder: pathophysiology and novel tools for diagnosis and therapy", RF-2010-2309790, 2012-2016.
Coordinator of the Task: “Quality methods for Design of Experiments in Scientific Research”, qPMO CNR 2012-2015.
Scientific Coordinator of operative Unit, PRIN (Research Programs of National Interest) Project 2007 “Supramolecular complexes of sorcin in the generation and regulation of Calcium-dependent cellular functions”, 2008-2011.
Coordinator of the project "A new penta-EF protein in yeast: YGR058W. A possible role in the regulation of cell duplication", CNR.

ACTIVITIES

Since 2009: Member of NetwOrK, the Network for Outreach and Knowledge CNR
Since 2010: Coordinator for Technology Transfer for IBPM CNR.
Since 2010: Expert in the regional plan for experimental action for the innovation in technical formation. 
Since 2012: Co-founder and member of the Foresight Group CNR, a resource for making future scientific and technological choices for the CNR.
Since 2012: Co-founder of the qPMO (Quality and Project Management OpenLab) CNR.